The Cancer Drug Development Forum – CDDF is the platform for all stakeholders involved in the development of cancer drugs.

CDDF Webinar – Application of Artificial Intelligence in Leukemia Diagnostics: Implications for Clinical Trials and Cancer Drug Development

 

The Cancer Drug Development Forum organizes a live webinar regarding Application of Artificial Intelligence in Leukemia Diagnostics: Implications for Clinical Trials and Cancer Drug Development on Thursday 15 October 2020 from 6PM to 7PM (CEST) / 12PM to 1PM (EDT) / 9AM to 10AM (PDT). This live webinar is composed of a 30-minute lecture given by Prof. Torsten Haferlach (MLL Munich Leukemia Laboratory) followed by a 30-minute discussion session.  

WEBINAR OUTLINE

Leukaemia diagnostics depends on phenotypes and experienced personnel. The new options of artificial intelligence, machine learning and cloud computing offer fascinating options to achieve better diagnostic accuracy and improved therapeutic selection. This talk will demonstrate how these technologies are already used in a routine, accredited workflow and how they may change future drug development for haematological malignancies.

DATE & TIME

  • Thursday 15 October 2020
  • 6PM to 7PM (CEST) / 12PM to 1PM (EDT) / 9AM to 10AM (PDT).

SPEAKER

Prof Dr Dr Torsten Haferlach, CEO, MLL Munich Leukemia Laboratory

Prof Dr Dr Torsten Haferlach is one of the world’s leading experts in the field of leukemia; engaging in ground breaking research, the development of new diagnostic tools as well as the link to treatment options, he has always been pushing its boundaries of his chosen field, now also introducing AI in routine workflows of leukemia diagnostics.

With an MD in medicine as well as a PhD in Germanistics, and a habilitation that already sets standards in the leukemia diagnostic  field, he spent the first part of his career as a medical doctor and hematologist, first at the university clinics in Kiel and Göttingen then at the university clinic in Munich where he acted as both the senior physician at the Department of Internal Medicine and the Head of the laboratory for leukaemia diagnostics.

In 2005 he set up the Munich Leukemia Laboratory (www.mll.com) together with three colleagues from complementary disciplines. Today the lab processes with a team of 210 employees over 88,000 blood or bone marrow samples per year, his practice treats more than 4,500 patients, and he is one of the major contributors to knowledge in this area: well over 570 articles have been published in top ranking, peer-reviewed medical journals since the lab’s inception.

 

MODERATORS

The webinar is moderated by the two CDDF Board Members:

 

PROGRAMME

  • 6.00PM-6.05PM (CEST): Introduction (CDDF)
  • 6.05PM-6.35PM (CEST): Lecture (Prof. Torsten Haferlach)
  • 6.35PM-7.00PM (CEST): Q&A / discussion session (moderated by Prof. Axel Glasmacher and Prof. Ruth Plummer, CDDF)

 

Meeting Materials

  • A video recording and presentation slides will be available to the public as of 15 October 2021

 

Cancer Drug Development Forum asbl
Registered office: c/o BLSI, Clos Chapelle-aux-Champs 30, 1200 Woluwe Saint Lambert, Belgium
Register of legal entities: the French Speaking Enterprise Court in Brussels
Enterprise number: 738.523.752

info@cddf.org
Tel: +32 2 880 62 70